These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 21440603)

  • 1. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.
    Yamagishi S; Maeda S; Matsui T; Ueda S; Fukami K; Okuda S
    Biochim Biophys Acta; 2012 May; 1820(5):663-71. PubMed ID: 21440603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
    Yamagishi S
    Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bone metabolism and cardiovascular function update. Impairment of osteo-vascular interaction by glyco-oxidative stress].
    Yamagishi SI
    Clin Calcium; 2014 Jul; 24(7):85-91. PubMed ID: 24976060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
    Yamagishi S
    Ther Apher Dial; 2009 Dec; 13(6):534-9. PubMed ID: 19954478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease.
    Yamagishi S; Fukami K; Matsui T
    Int J Cardiol; 2015 Apr; 185():263-8. PubMed ID: 25814214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders.
    Yamagishi S
    Rejuvenation Res; 2012 Dec; 15(6):564-72. PubMed ID: 22950433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
    Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T
    Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.
    Yamagishi S; Taguchi K; Fukami K
    Glycoconj J; 2016 Aug; 33(4):683-90. PubMed ID: 27338620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease.
    Yamagishi S; Nakamura K; Matsui T
    Pharmacol Res; 2009 Sep; 60(3):174-8. PubMed ID: 19646657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
    Yamagishi S; Matsui T; Nakamura K
    Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention.
    Yamagishi S; Matsui T
    Nutrition; 2016 Feb; 32(2):157-65. PubMed ID: 26602289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes.
    Yamagishi S
    Curr Drug Targets; 2011 Dec; 12(14):2096-102. PubMed ID: 22023404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(2):392-4. PubMed ID: 15922119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diabetic macrovascular complications].
    Yamagishi S
    Nihon Rinsho; 2015 Mar; 73(3):479-83. PubMed ID: 25812377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(5):953-5. PubMed ID: 15996828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of receptor for advanced glycation end products (RAGE) and its ligands in cancer risk.
    Yamagishi S; Matsui T; Fukami K
    Rejuvenation Res; 2015 Feb; 18(1):48-56. PubMed ID: 25472493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes.
    Yamagishi S; Matsui T; Nakamura K
    Med Hypotheses; 2008 Nov; 71(5):749-51. PubMed ID: 18710793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic intervention in diseases with advanced glycation end products in their pathogenesis].
    Zuwała-Jagiełło J
    Pol Merkur Lekarski; 2009 Aug; 27(158):152-6. PubMed ID: 19856885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced interaction of advanced glycation end products with their cellular receptor RAGE: implications for the pathogenesis of accelerated periodontal disease in diabetes.
    Lalla E; Lamster IB; Schmidt AM
    Ann Periodontol; 1998 Jul; 3(1):13-9. PubMed ID: 9722686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory.
    Yamagishi SI; Nakamura N; Matsui T
    J Diabetes; 2017 Feb; 9(2):141-148. PubMed ID: 27556881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.